**Table S2. Characteristics of patients with colorectal cancer classified by CIN status.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Number of patients n (%)** | **CIN-L/0** | **CIN-H** | **Total** | ***p*** |
| 37 (44) | 48 (56) | 85 |   |
| **Gender** | **Female** | 11 (30) | 18 (38) | 29 | 0,60 |
|  | **Male** | 26 (70) | 30 (62) | 56 | 0 |
| **Age (years)** | **< 60**  | 10 (27) | 16 (33) | 26 | 0,70 |
|  | **≥ 60** | 27 (73) | 32 (67) | 59 |   |
| **Localization** | **Right** | 12 (32) | 7 (15) | 19 | 0,09 |
|  | **Left** | 25 (68) | 41 (85) | 66 |   |
| **Vascular Invasion** | **No** | 23 (62) | 30 (62) | 53 | 0,85 |
| **Yes** | 14 (38) | 18 (38) | 32 |   |
| **Lymphovascular Invasion** | **No** | 25 (68) | 31 (65) | 56 | 0,97 |
| **Yes** | 11 (29) | 15 (31) | 26 |   |
| **NI** | 1 (3) | 2 (4) | 3 |   |
| **Lymphocytic Infiltration (TILs)** | **No** | 4 (11) | 4 (8) | 8 | 0,94 |
| **Yes** | 24 (65) | 34 (71) | 58 |   |
| **NI** | 9 (24) | 10 (21) | 19 |   |
| **Differentiation** | **Well** | 0 (0) | 2 (4) | 2 | 0,76 |
| **Moderate** | 34 (92) | 44 (92) | 78 |   |
| **Poor** | 3 (8) | 2 (4) | 5 |   |
| **Mucin (cut-off 30%)** | **No** | 30 (81) | 42 (88) | 72 | 0,02\* |
| **Yes** | 6 (16) | 0 (0) | 6 |   |
| **NI** | 1 (3) | 6 (12) | 7 |   |
| **Tumor Budding**  | **Low** | 18 (49) | 25 (52) | 43 | 0,96 |
| **High** | 14 (38) | 17 (35) | 31 |   |
| **NI** | 5 (1) | 6 (13) | 11 |   |
| **Depth** | **pT1-T2** | 4 (11) | 8 (17) | 12 | 0,65 |
|  | **pT3-T4** | 33 (89) | 40 (83) | 73 |   |
|  | **pT1** | 2 (5) | 3 (6) | 5 |   |
|  | **pT2** | 2 (5) | 5 (10) | 7 |   |
|  | **pT3** | 28 (76) | 34 (71) | 62 |   |
|  | **pT4** | 5 (14) | 6 (13) | 11 |   |
| **Nodal Status** | **N0** | 22 (59) | 26 (54) | 48 |   |
|  | **N1** | 11 (30) | 16 (33) | 27 |   |
|  | **N2** | 4 (11) | 6 (13) | 10 |   |
| **AJCC TNM stage** | **I-II** | 21 (57) | 25 (52) | 46 | 0,83 |
| **III-IV** | 16 (43) | 23 (48) | 39 |   |
|  | **I** | 4 (11) | 7 (15) | 11 |   |
|  | **II** | 17 (46) | 18 (38) | 35 |   |
|  | **III** | 13 (35) | 18 (38) | 31 |   |
|  | **IV** | 3 (8) | 5 (10) | 8 |   |
| **MLH1 Methylation** | **UnMeth** | 35 (95) | 47 (98) | 82 | 0,82 |
| **Meth** | 2 (5) | 1 (2) | 3 |   |
| **MSI status** | **MSS/Low** | 37 (100) | 48 (100) | 85 |  |
| **MSI-High** | 0 (0) | 0 (0) | 0 |   |
| **CIMP status** | **Negative** | 11 (30) | 18 (38) | 29 | 0,99 |
| **Low** | 20 (54) | 21 (43) | 41 |   |
| **High** | 6 (16) | 9 (19) | 15 |   |
| **KRAS** | **Wt** | 22 (59) | 37 (77) | 59 | 0,13 |
| **Mut** | 15 (41) | 11 (23) | 26 |   |
| **BRAF** | **Wt** | 37 (100) | 45 (94) | 82 | 0,34 |
| **Mut** | 0 (0) | 3 (6) | 3 |   |
| **PI3KCA** | **Wt** | 29 (78) | 40 (83) | 69 | 0,76 |
| **Mut** | 8 (22) | 8 (17) | 16 |   |

Values in the table represent numbers followed in parenthesis by %. Asterisks mean that the p-value is statistically significant. NI: Not Informed; Mut: mutated; Wt: wild-type; UnMeth: UnMethylated; Meth: Methylated; MSS: Microsatellite Stable; MSI-H: Microsatellite Instability-High; CIMP: CpG Island Methylator Phenotype; CIN: Chromosomal Instability; CIN-0/L: CIN-Negative/Low; CIN-H: CIN-High; AJCC: American Joint Committee on Cancer; TNM: tumor-node-metastasis. TILs: Tumor Infiltrating Lymphocytes. |
|
|
|